Evaluation of NovoRapid infusion as a treatment option in the manageme…
본문
R. Kwok, S. Sztal-Mazer, RE. Hopkins, SG. Poole, L. Grannell, J. Coutsouvelis, et al. (2017). Evaluation of NovoRapid infusion as a treatment option in the management of diabetic ketoacidosis. Internal medicine journal, 47(11), 1317-1320. https://doi.org/10.1111/imj.13607
[Abstract]
This study evaluates the clinical efficacy and safety of NovoRapid (insulin aspart) compared to Actrapid™ (human neutral insulin) for diabetic ketoacidosis (DKA). In this retrospective study involving 40 patients, no statistically significant differences were observed between biochemical variables, infusion duration or complications in patients treated with insulin aspart or human neutral insulin. These results support the use of insulin aspart as an effective and safe alternative to human neutral insulin in DKA.
댓글목록 0
등록된 댓글이 없습니다.
